We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Researchers Inhibit Metastasis in Mice with Cancer

By Biotechdaily staff writers
Posted on 11 Jun 2003
A modified version of a naturally occurring human protein can decrease the spread of human breast cancer implanted in mice. More...
The new findings were reported in the June 2003 issue of Clinical Cancer Research.

The ability to adhere to other cells is what allows a cell that breaks away from a primary tumor to lodge in other parts of the body, or metastasize. The researchers decided that interfering with that ability to adhere might be a way of attacking metastases. They modified a human protein known as galectin-3, a member of the family of proteins called lectins that bind to sugar molecules on the surface of cells. Galactin is known to promote cell-to-cell adhesion.

The researchers left the sugar-binding region of Galactin intact but removed the part of the protein that normally allows cells to stick to one another. Next, they implanted portions of human-derived breast cancer tumors into the chest pads of nude mice, which have a low-functioning immune system. Then they injected the experimental animals with the truncated galectin-3, while the control mice were given sham injections.

By the end of the experiment, the cancer had spread to lymph nodes or other organs in four out of 20 experimental mice, versus 11 of 20 controls. Also, the post-treatment growth of the tumor fragments was significantly less than in the control animals.

"We are able to significantly reduce the spread of the disease and decrease tumor growth without any evidence of toxicity,” said senior author Gary Jarvis, Ph.D., associate professor of laboratory medicine at the University of California, San Francisco ( USA; www.ucsf.edu). Dr. Jarvis and colleagues are now working on functional studies that would determine the mechanism behind the reduction in metastasis they observed.




Related Links:
University of California, San Francisco

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automated Urinalysis Solution
UN-9000
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.